MET and non-small cell lung carcinoma: Apart from those widely recognized alterations, such as EGFR and KRAS gene mutations, MET amplification, EML4-ALK rearrangements in NSCLC, somatic mutations and amplification in PIK3CA are described in 3–10% vs. 35% of SCC and 0–2.7% vs. 7% of ADC respectively [66].